A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2014565.pdf
Reference20 articles.
1. Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7: 353–370.
2. Canavese M, Santo L, Raje N (2012) Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther 13 (7): 451–457.
3. Cicenas J, Valius M (2011) The CDK inhibitors in cancer research and therapy. J Cancer Res Clin 137 (10): 1409–1418.
4. Finn RS, Dieras V, Gelmon KA, Harbeck N, Jones SE, Koehler M, Martin M, Rugo HS, Im S-A, Toi M, Gauthier ER, Huang X, Randolph S, Slamon DJ (2013) A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease. J Clin Oncol Meeting Abstracts 31 (15_suppl): TPS652.
5. Galons H, Oumata N, Gloulou O, Meijer L (2013) Cyclin-dependent kinase inhibitors closer to market launch? Expert Opin Ther Pat 23 (8): 945–963.
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09
2. Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium;Journal of Experimental & Clinical Cancer Research;2024-07-17
3. CDK9 inhibition activates innate immune response through viral mimicry;The FASEB Journal;2024-04-25
4. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors;Bioorganic & Medicinal Chemistry;2024-04
5. A precise prognostic signature in CTNNB1-mutant hepatocellular carcinoma: Prognosis prediction and precision treatment exploration;Heliyon;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3